Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 11/20 | 0.59 |
| ▸ | NPC1 | O15118 | 10/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | GALK1 | P51570 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13556232 | 0.85 | NPC1 (0.73) | ALDH1A1RAB9ANPC1MEN1KMT2A | |
| SCHEMBL13556275 | 0.84 | RAB9A (0.61) | ALDH1A1HPGDL3MBTL1RAB9ANPC1 | |
| SCHEMBL13701152 | 0.84 | RAB9A (0.74) | ALDH1A1HPGDL3MBTL1RAB9ANPC1 | |
| SCHEMBL12723651 | 0.77 | MAOB (0.61) | RAB9ANPC1MEN1KMT2APOLB | |
| SCHEMBL13556252 | 0.74 | MAOB (0.61) | RAB9ANPC1MEN1KMT2APOLB | |
| SCHEMBL11746037 | 0.74 | PIM1 (0.53) | ALDH1A1HPGDL3MBTL1RAB9ANPC1 | |
| SCHEMBL8252530 | 0.73 | ALDH1A1 (0.72) | ALDH1A1HPGDL3MBTL1RAB9ANPC1 | |
| SCHEMBL13556330 | 0.72 | CA12 (0.50) | ALDH1A1HPGDL3MBTL1RAB9ANPC1 | |
| SCHEMBL6817708 | 0.72 | RAB9A (0.63) | ALDH1A1HPGDL3MBTL1RAB9ANPC1 | |
| SCHEMBL2270361 | 0.71 | RAB9A (0.59) | HPGDL3MBTL1RAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | ALDH1A1 668/4885HPGD 870/4885L3MBTL1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.